Prime Medicine, Inc. (PRME) Price & Analysis

Compare

718 Followers

PRME Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.11 - $5.62

Previous CloseN/A

Volume144.88K

Average Volume (3M)5.06M

Market Cap

$515.12M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta3.27

Next Earnings

Aug 06, 2025

EPS Estimate

-0.35

Last Dividend Ex-Date

Sep 10, 2019

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding134,496,020

10 Day Avg. Volume4,292,032

30 Day Avg. Volume5,064,048

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$6.30

Price Target Upside68.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Funding And ValidationAdditional $24M funding from CF Foundation provides validation to PRME's CF program and prime editing platform.

Potential AcquisitionVerve's acquisition by Lilly for $1.3BN has been a key factor behind the momentum of Prime Medicine's stock.

Technological AdvancementPRME's prime editing technology shows promise, reflected by the 90% editing efficiency in the 2nd patient treated ex vivo.

Bears Say

Acquisition UncertaintyIt is unlikely that an acquisition will happen without clinical data from their Wilson Disease or AATD programs.

Financial ConcernsThe funding is unlikely to resolve Prime’s near-term financial overhang.

Regulatory And Clinical RisksA Neutral rating is maintained on PRME due to the lack of near-term meaningful catalysts, as well as financial and legal uncertainties.

Prime Medicine, Inc. News

Cathie Wood Buys $69M Worth of Figma Stock on Blockbuster IPO Debut

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) snapped up 60,000 shares of newly-listed tech company Figma ($FIG) on July 31....

6h ago

AMD

Prime Medicine 38M share Spot Secondary priced at $3.30

TD Cowen and BMO Capital are acting as joint book running managers for the offering. The deal priced...

2d ago

PRME

Prime Medicine announces common stock offering, no amount given

Prime Medicine (PRME) announced that it has commenced an underwritten public offering of shares of its common stock....

2d ago

PRME

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Blaize Holdings Inc (BZAI)...

5d ago

SLI

AAPL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Ouster Inc (OUST) 1.87%...

12d ago

QID

ABSI

Prime Medicine announces additional funding of up to $24M from CF Foundation

Prime Medicine (PRME) announced that the Cystic Fibrosis Foundation has agreed to provide the Company with up to...

17d ago

PRME

JonesResearch lists factors for Prime Medicine continued share rally

JonesResearch says Prime Medicine (PRME) continues to rally following the management change on May 19, rallying $160% since...

25d ago

PRME

VERV

Prime Medicine Announces $120.2M Public Stock Offering

Prime Medicine, Inc. ( ($PRME) ) just unveiled an update. On July 30, 2025, Prime Medicine, Inc. entered...

1d ago

PRME

Prime Medicine Halts Sales Agreement Prospectus

Prime Medicine, Inc. ( ($PRME) ) has provided an update. On July 30, 2025, Prime Medicine, Inc. terminated...

2d ago

PRME

Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Prime Medicine, Inc. yesterday and set a price...

16d ago

PRME

Prime Medicine Announces CSO Resignation and Transition

An update from Prime Medicine, Inc. ( ($PRME) ) is now available. On July 14, 2025, Prime Medicine,...

17d ago

PRME

Prime Medicine, Inc.: Buy Rating Driven by Strategic Positioning and Market Momentum

Prime Medicine, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy...

26d ago

PRME

Prime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment Opportunity

JonesTrading analyst Soumit Roy maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report) today and...

2M ago

PRME

Prime Medicine Elects Directors at Annual Meeting

Prime Medicine, Inc. ( ($PRME) ) has shared an update. On June 4, 2025, Prime Medicine, Inc. held...

2M ago

PRME

PRME FAQ

What was Prime Medicine, Inc.’s price range in the past 12 months?

Prime Medicine, Inc. lowest stock price was $1.11 and its highest was $5.62 in the past 12 months.

What is Prime Medicine, Inc.’s market cap?

Prime Medicine, Inc.’s market cap is $515.12M.

When is Prime Medicine, Inc.’s upcoming earnings report date?

Prime Medicine, Inc.’s upcoming earnings report date is Aug 06, 2025 which is in 4 days.

How were Prime Medicine, Inc.’s earnings last quarter?

Prime Medicine, Inc. released its earnings results on May 08, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.313 by -$0.087.

Is Prime Medicine, Inc. overvalued?

According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Prime Medicine, Inc. pay dividends?

Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here

What is Prime Medicine, Inc.’s EPS estimate?

Prime Medicine, Inc.’s EPS estimate is -0.35.

How many shares outstanding does Prime Medicine, Inc. have?

Prime Medicine, Inc. has 134,496,020 shares outstanding.

What happened to Prime Medicine, Inc.’s price movement after its last earnings report?

Prime Medicine, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.313. Following the earnings report the stock price went down -7.042%.

Which hedge fund is a major shareholder of Prime Medicine, Inc.?

Currently, no hedge funds are holding shares in PRME

Prime Medicine, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-115.21%

Trailing 12-Months

Asset Growth

5.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Prime Medicine, Inc.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc. (PRME) Earnings & Revenues

PRME Earnings Data >

PRME Stock 12 Month Forecast

Average Price Target

$6.30

▲(68.45%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.73,3.289230769230769,3.8484615384615384,4.407692307692308,4.966923076923077,5.526153846153846,6.085384615384616,6.644615384615385,7.203846153846154,7.763076923076923,8.322307692307692,8.881538461538462,9.44076923076923,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.73,3.0046153846153847,3.279230769230769,3.5538461538461537,3.8284615384615384,4.103076923076923,4.377692307692308,4.6523076923076925,4.926923076923076,5.201538461538462,5.476153846153846,5.75076923076923,6.025384615384615,{"y":6.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.73,2.6353846153846154,2.540769230769231,2.4461538461538463,2.3515384615384614,2.256923076923077,2.1623076923076923,2.0676923076923077,1.9730769230769232,1.8784615384615384,1.7838461538461539,1.6892307692307693,1.5946153846153845,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.76,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.27,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.19,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >